<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04358744</url>
  </required_header>
  <id_info>
    <org_study_id>XH-20-005</org_study_id>
    <nct_id>NCT04358744</nct_id>
  </id_info>
  <brief_title>The Real World Study of Autism Spectrum Disorder in China</brief_title>
  <official_title>The Real World Study of Children With Autism Spectrum Disorder in China</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xinhua Hospital, Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xinhua Hospital, Shanghai Jiao Tong University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators conduct the real world study to explore mechanisms of autism based on
      multi-modal data.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Children with autism spectrum disorder registered in Xinhua Hospital are measured in aspects
      of behavioural accessment, genetic test, blood lab test, gut microbiome and neuroimaging
      including structural and functional magnetic resonance imaging (MRI), functional near -
      infrared spectroscopy(f-NIRS), electroencephalography and eye movement. The investigators
      conduct the real world study to explore mechanisms of autism based on the multi-modal data.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 13, 2019</start_date>
  <completion_date type="Anticipated">September 2024</completion_date>
  <primary_completion_date type="Anticipated">September 2024</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Year</target_duration>
  <primary_outcome>
    <measure>Behaviour assessment</measure>
    <time_frame>The baseline and 3 months</time_frame>
    <description>The behaviour development of participants includes intellectual/developmental quotient, syptoms severity, comorbidity, etc.</description>
  </primary_outcome>
  <other_outcome>
    <measure>Genetic characteristics</measure>
    <time_frame>The baseline</time_frame>
    <description>Genome wide association study from blood sample</description>
  </other_outcome>
  <other_outcome>
    <measure>Blood test</measure>
    <time_frame>The baseline and 3 months</time_frame>
    <description>Retained blood samples tested in immunomics, metabonomics, etc</description>
  </other_outcome>
  <other_outcome>
    <measure>Blood test</measure>
    <time_frame>The baseline and 6 months</time_frame>
    <description>Retained blood samples tested in immunomics, metabonomics, etc</description>
  </other_outcome>
  <other_outcome>
    <measure>Blood test</measure>
    <time_frame>The baseline and 12 months</time_frame>
    <description>Retained blood samples tested in immunomics, metabonomics, etc</description>
  </other_outcome>
  <other_outcome>
    <measure>Gut mircobiome</measure>
    <time_frame>The baseline and 1 months</time_frame>
    <description>Retained stool samples tested in metabonomics, genomics, etc</description>
  </other_outcome>
  <other_outcome>
    <measure>Gut mircobiome</measure>
    <time_frame>The baseline and 3 months</time_frame>
    <description>Retained stool samples tested in metabonomics, genomics, etc</description>
  </other_outcome>
  <other_outcome>
    <measure>Gut mircobiome</measure>
    <time_frame>The baseline and 6 months</time_frame>
    <description>Retained stool samples tested in metabonomics, genomics, etc</description>
  </other_outcome>
  <other_outcome>
    <measure>Gut mircobiome</measure>
    <time_frame>The baseline and 12 months</time_frame>
    <description>Retained stool samples tested in metabonomics, genomics, etc</description>
  </other_outcome>
  <other_outcome>
    <measure>Head Magnetic Resonance Imaging (Head MRI)</measure>
    <time_frame>The baseline and 3 months</time_frame>
    <description>Head MRI is used to detect the structure and function of the brain.</description>
  </other_outcome>
  <other_outcome>
    <measure>Head Magnetic Resonance Imaging (Head MRI)</measure>
    <time_frame>The baseline and 12 months</time_frame>
    <description>Head MRI is used to detect the structure and function of the brain.</description>
  </other_outcome>
  <other_outcome>
    <measure>Functional near - infrared spectroscopy(f-NIRS)</measure>
    <time_frame>The baseline and 3 months</time_frame>
    <description>Head fNIRs is a non-invasive, non-ionizing method for measuring and imaging the functional hemodynamic response to brain activity. It measures changes in hemoglobin (Hb) concentrations within the brain by means of the characteristic absorption spectra of Hb in the near-infrared range.</description>
  </other_outcome>
  <other_outcome>
    <measure>Functional near - infrared spectroscopy(f-NIRS)</measure>
    <time_frame>The baseline and 6 months</time_frame>
    <description>Head fNIRs is a non-invasive, non-ionizing method for measuring and imaging the functional hemodynamic response to brain activity. It measures changes in hemoglobin (Hb) concentrations within the brain by means of the characteristic absorption spectra of Hb in the near-infrared range.</description>
  </other_outcome>
  <other_outcome>
    <measure>Functional near - infrared spectroscopy(f-NIRS)</measure>
    <time_frame>The baseline and 12 months</time_frame>
    <description>Head fNIRs is a non-invasive, non-ionizing method for measuring and imaging the functional hemodynamic response to brain activity. It measures changes in hemoglobin (Hb) concentrations within the brain by means of the characteristic absorption spectra of Hb in the near-infrared range.</description>
  </other_outcome>
  <other_outcome>
    <measure>Multichannel Electroencephalography signals</measure>
    <time_frame>The baseline and 3 months</time_frame>
    <description>The latency and amplitude measured by electroencephalogram can reflect the connectivity between brain regions.</description>
  </other_outcome>
  <other_outcome>
    <measure>Multichannel Electroencephalography signals</measure>
    <time_frame>The baseline and 6 months</time_frame>
    <description>The latency and amplitude measured by electroencephalogram can reflect the connectivity between brain regions.</description>
  </other_outcome>
  <other_outcome>
    <measure>Multichannel Electroencephalography signals</measure>
    <time_frame>The baseline and 12 months</time_frame>
    <description>The latency and amplitude measured by electroencephalogram can reflect the connectivity between brain regions.</description>
  </other_outcome>
  <other_outcome>
    <measure>Eye movements</measure>
    <time_frame>The baseline and 3 months</time_frame>
    <description>Variables measured by eye movements represent cognition.</description>
  </other_outcome>
  <other_outcome>
    <measure>Eye movements</measure>
    <time_frame>The baseline and 6 months</time_frame>
    <description>Variables measured by eye movements represent cognition.</description>
  </other_outcome>
  <other_outcome>
    <measure>Eye movements</measure>
    <time_frame>The baseline and 12 months</time_frame>
    <description>Variables measured by eye movements represent cognition.</description>
  </other_outcome>
  <other_outcome>
    <measure>Behaviour assessment</measure>
    <time_frame>The baseline and 6 months</time_frame>
    <description>The behaviour development of participants includes intellectual/developmental quotient, syptoms severity, comorbidity, etc.</description>
  </other_outcome>
  <other_outcome>
    <measure>Behaviour assessment</measure>
    <time_frame>The baseline and 12 months</time_frame>
    <description>The behaviour development of participants includes intellectual/developmental quotient, syptoms severity, comorbidity, etc.</description>
  </other_outcome>
  <enrollment type="Anticipated">2500</enrollment>
  <condition>Autism Spectrum Disorder</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood and stool samples are retained in Xinhua
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Children with autism spectrum disorder have registered in Xinhua hospital and provided
        written informed consent from themselves and/or their legal guardians.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diagnosed with autism spectrum disorder

          -  registered in Xinhua hospital

          -  written informed consent provided

        Exclusion Criteria:

          -  NA
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Months</minimum_age>
    <maximum_age>18 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Fei Li, doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Xinhua hospital Affilated to Shanghai Jiao Tong University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fei Li, doctor</last_name>
    <phone>+86-21-25077461</phone>
    <email>feili@shsmu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>ShanghaiXinhua</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200092</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fei Li, Director</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 20, 2020</study_first_submitted>
  <study_first_submitted_qc>April 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 24, 2020</study_first_posted>
  <last_update_submitted>June 11, 2020</last_update_submitted>
  <last_update_submitted_qc>June 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Autistic Disorder</mesh_term>
    <mesh_term>Autism Spectrum Disorder</mesh_term>
    <mesh_term>Child Development Disorders, Pervasive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

